LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 8197

Search options

  1. Article ; Online: Authors' Reply.

    De Vriese, An S

    Journal of the American Society of Nephrology : JASN

    2021  Volume 32, Issue 9, Page(s) 2390–2391

    Language English
    Publishing date 2021-08-18
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1085942-1
    ISSN 1533-3450 ; 1046-6673
    ISSN (online) 1533-3450
    ISSN 1046-6673
    DOI 10.1681/ASN.2021060866
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation.

    Dhaese, Sofie A M / De Vriese, An S

    Mayo Clinic proceedings

    2023  Volume 98, Issue 5, Page(s) 750–770

    Abstract: The optimal approach to prevent stroke and systemic embolism in patients with advanced chronic kidney disease (CKD) and atrial fibrillation remains unresolved. We conducted a narrative review to explore areas of uncertainty and opportunities for future ... ...

    Abstract The optimal approach to prevent stroke and systemic embolism in patients with advanced chronic kidney disease (CKD) and atrial fibrillation remains unresolved. We conducted a narrative review to explore areas of uncertainty and opportunities for future research. First, the relationship between atrial fibrillation and stroke is more complex in patients with advanced CKD than in the general population. The currently employed risk stratification tools do not adequately discriminate between patients deriving a net benefit and those suffering a net harm from oral anticoagulation. Anticoagulation initiation should probably be more restrictive than is currently advocated by official guidelines. Recent evidence reveals that the superior benefit-risk profile of non-vitamin K antagonist oral anticoagulants (NOACs) vs vitamin K antagonists (VKAs) observed in the general population and in moderate CKD can be extended to advanced CKD. The NOACs yield better protection against stroke, cause less major bleeding, are associated with less acute kidney injury and a slower decline of CKD, and are associated with a lower incidence of cardiovascular events than VKAs. The VKAs may be harmful in CKD patients, in particular in patients with a high bleeding risk and labile international normalized ratio. The better safety and efficacy of NOACs as opposed to VKAs may be particularly evident in advanced CKD as a result of better on-target anticoagulation with NOACs, harmful off-target vascular effects of VKAs, and beneficial off-target vascular effects of NOACs. The intrinsic vasculoprotective effects of NOACs are supported by animal experimental evidence as well as by findings of large clinical trials and may result in use of NOACs beyond their anticoagulant properties.
    MeSH term(s) Humans ; Atrial Fibrillation/complications ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/chemically induced ; Anticoagulants/adverse effects ; Administration, Oral ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Stroke/etiology ; Stroke/prevention & control ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy
    Chemical Substances Anticoagulants
    Language English
    Publishing date 2023-04-05
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 124027-4
    ISSN 1942-5546 ; 0025-6196
    ISSN (online) 1942-5546
    ISSN 0025-6196
    DOI 10.1016/j.mayocp.2023.01.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Treatment of IgA Nephropathy: A Rapidly Evolving Field.

    El Karoui, Khalil / Fervenza, Fernando C / De Vriese, An S

    Journal of the American Society of Nephrology : JASN

    2023  Volume 35, Issue 1, Page(s) 103–116

    Abstract: The pivotal event in the pathophysiology of IgA nephropathy is the binding of circulating IgA-containing immune complexes to mesangial cells, with secondary glomerular and tubulointerstitial inflammation and fibrosis. The paramount difficulty in the ... ...

    Abstract The pivotal event in the pathophysiology of IgA nephropathy is the binding of circulating IgA-containing immune complexes to mesangial cells, with secondary glomerular and tubulointerstitial inflammation and fibrosis. The paramount difficulty in the management of IgA nephropathy is the heterogeneity in its clinical presentation and prognosis, requiring an individualized treatment approach. Goal-directed supportive care remains the bedrock of therapy for all patients, regardless of risk of progression. Sodium-glucose transporter 2 inhibitors and sparsentan should be integral to contemporary supportive care, particularly in patients with chronic kidney damage. Pending the development of reliable biomarkers, it remains a challenge to identify patients prone to progression due to active disease and most likely to derive a net benefit from immunosuppression. The use of clinical parameters, including the degree of proteinuria, the presence of persistent microscopic hematuria, and the rate of eGFR loss, combined with the mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, crescents score, is currently the best approach. Systemic glucocorticoids are indicated in high-risk patients, but the beneficial effects wane after withdrawal and come at the price of substantial treatment-associated toxicity. Therapies with direct effect on disease pathogenesis are increasingly becoming available. While targeted-release budesonide has garnered the most attention, anti-B-cell strategies and selective complement inhibition will most likely prove their added value. We propose a comprehensive approach that tackles the different targets in the pathophysiology of IgA nephropathy according to their relevance in the individual patient.
    MeSH term(s) Humans ; Glomerulonephritis, IGA/drug therapy ; Glomerulonephritis, IGA/complications ; Kidney Glomerulus/pathology ; Glomerulosclerosis, Focal Segmental/pathology ; Prognosis ; Fibrosis
    Language English
    Publishing date 2023-09-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1085942-1
    ISSN 1533-3450 ; 1046-6673
    ISSN (online) 1533-3450
    ISSN 1046-6673
    DOI 10.1681/ASN.0000000000000242
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Acute glomerulonephritis.

    Sethi, Sanjeev / De Vriese, An S / Fervenza, Fernando C

    Lancet (London, England)

    2022  Volume 399, Issue 10335, Page(s) 1646–1663

    Abstract: Glomerulonephritis is a heterogeneous group of disorders that present with a combination of haematuria, proteinuria, hypertension, and reduction in kidney function to a variable degree. Acute presentation with full blown nephritic syndrome or rapidly ... ...

    Abstract Glomerulonephritis is a heterogeneous group of disorders that present with a combination of haematuria, proteinuria, hypertension, and reduction in kidney function to a variable degree. Acute presentation with full blown nephritic syndrome or rapidly progressive glomerulonephritis is uncommon and is mainly restricted to patients with post-infectious glomerulonephritis, anti-neutrophil cytoplasmic antibodies-associated vasculitis, and anti-glomerular basement membrane disease. Most frequently, patients present with asymptomatic haematuria and proteinuria with or without reduced kidney function. All glomerulonephritis disorders can show periods of exacerbation, but disease flairs characteristically occur in patients with IgA nephropathy or C3 glomerulopathy. The gold standard for the diagnosis of a glomerulonephritis is a kidney biopsy, with a hallmark glomerular inflammation that translates into various histopathological patterns depending on the location and severity of the glomerular injury. Traditionally, glomerulonephritis was classified on the basis of the different histopathological patterns of injury. In the last few years, substantial progress has been made in unravelling the underlying causes and pathogenetic mechanisms of glomerulonephritis and a causal approach to the classification of glomerulonephritis is now favoured over a pattern-based approach. As such, glomerulonephritis can be broadly classified as immune-complex glomerulonephritis (including infection-related glomerulonephritis, IgA nephropathy, lupus nephritis, and cryoglobulinaemic glomerulonephritis), anti-neutrophil cytoplasmic antibodies-associated (pauci-immune) glomerulonephritis, anti-glomerular basement membrane glomerulonephritis, C3 glomerulopathy, and monoclonal immunoglobulin-associated glomerulonephritis. We provide an overview of the clinical presentation, pathology, and the current therapeutic approach of the main representative disorders in the spectrum of glomerulonephritis.
    MeSH term(s) Antibodies, Antineutrophil Cytoplasmic/analysis ; Antibodies, Antineutrophil Cytoplasmic/therapeutic use ; Biopsy/adverse effects ; Female ; Glomerulonephritis/pathology ; Glomerulonephritis, IGA ; Hematuria/etiology ; Humans ; Male ; Proteinuria/complications
    Chemical Substances Antibodies, Antineutrophil Cytoplasmic
    Language English
    Publishing date 2022-04-24
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(22)00461-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.

    El Karoui, Khalil / De Vriese, An S

    Kidney international

    2022  Volume 101, Issue 5, Page(s) 883–894

    Abstract: The COVID-19 pandemic has profound adverse effects on the population on dialysis. Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality, and many have experienced psychological distress as well as delayed or ... ...

    Abstract The COVID-19 pandemic has profound adverse effects on the population on dialysis. Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality, and many have experienced psychological distress as well as delayed or suboptimal care. COVID-19 survivors have prolonged viral shedding, but generally develop a robust and long-lasting humoral immune response that correlates with initial disease severity. However, protection against reinfection is incomplete. A growing body of evidence reveals delayed and blunted immune responses to SARS-CoV-2 vaccination. Administration of a third dose within 1 to 2 months of prime-boost vaccination significantly increases antibody levels, in particular in patients with poor initial responses. Patients on dialysis have inferior immune responses to adenoviral vector vaccines than to mRNA vaccines. The immunogenicity of the mRNA-1273 vaccine is markedly better than that of the BNT162b2 vaccine, most likely by virtue of its higher mRNA content. Despite suboptimal immune responses in patients on dialysis, preliminary data suggest that vaccination partially protects against infection and severe disease requiring hospitalization. However, progressive waning of immunity and emergence of SARS-CoV-2 variants with a high potential of immune escape call for a booster dose in all patients on dialysis 4 to 6 months after prime-boost vaccination. Patients with persistent poor vaccine responses may be candidates for primary prophylaxis strategies. In the absence of specific data in patients on dialysis, therapeutic strategies in the event of established COVID-19 must be extrapolated from evidence obtained in the population not on dialysis. Neutralizing monoclonal antibodies may be an attractive option after a high-risk exposure or during the early course of infection.
    MeSH term(s) 2019-nCoV Vaccine mRNA-1273 ; Antibodies, Viral ; BNT162 Vaccine ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Immunity, Humoral ; Pandemics/prevention & control ; Renal Dialysis/adverse effects ; SARS-CoV-2 ; Vaccination
    Chemical Substances Antibodies, Viral ; COVID-19 Vaccines ; 2019-nCoV Vaccine mRNA-1273 (EPK39PL4R4) ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2022-02-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2022.01.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Should Statins Be Banned from Dialysis?

    De Vriese, An S

    Journal of the American Society of Nephrology : JASN

    2017  Volume 28, Issue 6, Page(s) 1675–1676

    MeSH term(s) Clinical Decision-Making ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Kidney Failure, Chronic/therapy ; Male ; Practice Guidelines as Topic ; Prognosis ; Renal Dialysis/adverse effects ; Renal Dialysis/methods ; Risk Assessment ; Societies, Medical/standards ; Treatment Outcome ; Vascular Calcification/chemically induced ; Vascular Calcification/physiopathology
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Language English
    Publishing date 2017-05-03
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 1085942-1
    ISSN 1533-3450 ; 1046-6673
    ISSN (online) 1533-3450
    ISSN 1046-6673
    DOI 10.1681/ASN.2017020201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: In Reply to 'Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?'

    De Vriese, An S / Reynders, Marijke

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2020  Volume 76, Issue 4, Page(s) 598–599

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; Renal Dialysis ; SARS-CoV-2 ; Severe Acute Respiratory Syndrome
    Keywords covid19
    Language English
    Publishing date 2020-06-27
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2020.06.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: PEXIVAS: The End of Plasmapheresis for ANCA-Associated Vasculitis?

    De Vriese, An S / Fervenza, Fernando C

    Clinical journal of the American Society of Nephrology : CJASN

    2020  Volume 16, Issue 2, Page(s) 307–309

    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/therapy ; Humans ; Kidney Diseases/etiology ; Plasma Exchange ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2020-09-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.10550620
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis.

    De Vriese, An S / Reynders, Marijke

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2020  Volume 76, Issue 3, Page(s) 440–441

    MeSH term(s) Autoantibodies/isolation & purification ; Autoantibodies/metabolism ; Betacoronavirus/isolation & purification ; Betacoronavirus/metabolism ; COVID-19 ; Coronavirus Infections/metabolism ; Coronavirus Infections/therapy ; Humans ; Immunoglobulin G/metabolism ; Pandemics ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/therapy ; RNA, Viral/isolation & purification ; RNA, Viral/metabolism ; Renal Dialysis/trends ; SARS-CoV-2
    Chemical Substances Autoantibodies ; Immunoglobulin G ; RNA, Viral
    Keywords covid19
    Language English
    Publishing date 2020-06-05
    Publishing country United States
    Document type Letter
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2020.05.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients.

    De Vriese, An S / Van Praet, Jens / Reynders, Marijke / Heylen, Line / Viaene, Liesbeth / Caluwé, Rogier / Schoutteten, Melanie / De Bacquer, Dirk

    Kidney international reports

    2022  Volume 7, Issue 5, Page(s) 1103–1107

    Language English
    Publishing date 2022-02-22
    Publishing country United States
    Document type Journal Article
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2022.02.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top